EXAI 5.14 Exscientia plc
| Range: | 3.8-7.91 | Vol Avg: | 674743 | Last Div: | 0 | Changes: | 0.26 |
| Beta: | 0.84 | Cap: | 0.63B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 01 2021 | Empoloyees: | 483 | ||
| CUSIP: | 30223G102 | CIK: | 0001865408 | ISIN: | US30223G1022 | Country: | GB |
| CEO: | Dr. David Hallett Ph.D. | Website: | https://www.exscientia.ai | ||||
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Stock Details
Positive 0.17
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the advanc...
businesswire.com·Wed Oct 16 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow